US government advisers have recommended changing the design of Covid-19 vaccines to target the Omicron variant for a booster campaign aimed at blunting an expected surge of infections in the autumn. Scientists on a Food and Drug Administration advisory committee on Tuesday voted 19 to two in favour of incorporating genetic material from the fast-spreading Omicron variant into a new generation of booster jabs. The recommendation, if approved by US authorities, would pave the way for Moderna and Pfizer to switch manufacturing operations over to making vaccines that experts believe will provide better protection against the most widely circulating Covid variants.
In the latest trading session, Moderna (MRNA) closed at $145.36, marking a +0.76% move from the previous day.
Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.